Retraction
Thyroid Cancer Cell Resistance to Gefitinib Depends on the Constitutive Oncogenic Activation of the ERK Pathway
Paper Information
Record ID:
42907
Author(s):
Publication Date:
April 04, 2013
Retraction Date:
February 28, 2023
(2.7 years years ago)
Subjects:
Institutions:
- Department of Clinical and Molecular Bio-Medicine, Endocrinology Unit, University of Catania, Garibaldi Nesima Medical Center, 95122 Catania, Italy
- Garibaldi Nesima Medical Center, 95122 Catania, Italy
- Department of Clinical and Molecular Bio-Medicine, Section of Hematology, Oncology, University of Catania, 95124 Catania, Italy
- General Pathology, University of Catania, 95124 Catania, Italy
- Facolta di Scienze delle Attivita Motorie e Sportive, “Kore” University of Enna, University Campus, 94100 Enna, Italy
- Humanitas, Centro Catanese di Oncologia, 95126, Catania, Italy
Country:
🇮🇹 ItalyArticle Type:
Publisher:
Oxford Academic
Open Access:
Yes
DOI:
PubMed ID:
Retraction PubMed ID:
Retraction Details
Citations (19)
19
Total Citations0
Post-Retraction19
Pre-Retraction0
Same DayGenetic alterations shaping tumor response to anti-EGFR therapies
Javier Vaquero, Allan Pavy, Ester Gonzalez‐Sanchez et al. (6 authors)
Drug Resistance Updates
Published: Aug 2022
17 citations
17 citations
184 days before retraction
Emerging Role of Oxidative Stress on EGFR and OGG1-BER Cross-Regulation: Implications in Thyroid Physiopathology
Carmelo Moscatello, Maria Carmela Di Marcantonio, Luca Savino et al. (11 authors)
Cells
Open Access
Published: Feb 2022
13 citations
13 citations
367 days before retraction
The Possible Role of Cancer Stem Cells in the Resistance to Kinase Inhibitors of Advanced Thyroid Cancer
Fiorenza Gianì, Veronica Vella, Dario Tumino et al. (5 authors)
Cancers
Open Access
Published: Aug 2020
19 citations
19 citations
931 days before retraction
10D1F, an Anti-HER3 Antibody That Uniquely Blocks the Receptor Heterodimerization Interface, Potently Inhibits Tumor Growth Across a Broad Panel of Tumor Models
Dipti Thakkar, Vicente Sancenón, Marvin M. Taguiam et al. (9 authors)
Molecular Cancer Therapeutics
Open Access
Published: Jan 2020
13 citations
13 citations
1147 days before retraction
Insulin Receptor Isoform A Modulates Metabolic Reprogramming of Breast Cancer Cells in Response to IGF2 and Insulin Stimulation
Veronica Vella, Maria Luisa Nicolosi, Marika Giuliano et al. (6 authors)
Cells
Open Access
Published: Sep 2019
30 citations
30 citations
1276 days before retraction
HRAS‐driven cancer cells are vulnerable to TRPML1 inhibition
Jewon Jung, Kwang‐Jin Cho, Ali Naji et al. (18 authors)
EMBO Reports
Open Access
Published: Feb 2019
78 citations
78 citations
1469 days before retraction
The Emerging Role of Insulin Receptor Isoforms in Thyroid Cancer: Clinical Implications and New Perspectives
Veronica Vella, Roberta Malaguarnera
International Journal of Molecular Sciences
Open Access
Published: Nov 2018
40 citations
40 citations
1551 days before retraction
Current controversies and future directions in the diagnosis and management of differentiated thyroid cancers
Timothy M. Ullmann, Katherine D. Gray, Maureen D. Moore et al. (5 authors)
Gland Surgery
Open Access
Published: Oct 2018
26 citations
26 citations
1611 days before retraction
The efficacy of HRAS and CDK4/6 inhibitors in anaplastic thyroid cancer cell lines
Sara Lopes-Ventura, Marta Pojo, Ana T. Matias et al. (7 authors)
Journal of Endocrinological Investigation
Published: Sep 2018
21 citations
21 citations
1636 days before retraction
DDR1 regulates thyroid cancer cell differentiation via IGF-2/IR-A autocrine signaling loop
Veronica Vella, Maria Luisa Nicolosi, P Cantafio et al. (11 authors)
Endocrine Related Cancer
Open Access
Published: Aug 2018
47 citations
47 citations
1655 days before retraction
EGFR inhibition enhances the antitumor efficacy of a selective BRAF V600E inhibitor in thyroid cancer cell lines
Yongsheng Jia, Cuicui Zhang, Chuanxiang Hu et al. (7 authors)
Oncology Letters
Open Access
Published: Feb 2018
8 citations
8 citations
1833 days before retraction
Insulin Resistance: Any Role in the Changing Epidemiology of Thyroid Cancer?
Roberta Malaguarnera, Veronica Vella, Maria Luisa Nicolosi et al. (4 authors)
Frontiers in Endocrinology
Open Access
Published: Nov 2017
56 citations
56 citations
1933 days before retraction
Discoidin domain receptor 1 modulates insulin receptor signaling and biological responses in breast cancer cells
Veronica Vella, Roberta Malaguarnera, Maria Luisa Nicolosi et al. (11 authors)
Oncotarget
Open Access
Published: May 2017
36 citations
36 citations
2111 days before retraction
PPAR-γ Agonists As Antineoplastic Agents in Cancers with Dysregulated IGF Axis
Veronica Vella, Maria Luisa Nicolosi, Stefania Giuliano et al. (6 authors)
Frontiers in Endocrinology
Open Access
Published: Feb 2017
75 citations
75 citations
2197 days before retraction
Metabolic Alterations of Thyroid Cancer as Potential Therapeutic Targets
Domenico Ciavardelli, Maria Bellomo, Ada Consalvo et al. (5 authors)
BioMed Research International
Open Access
Published: Jan 2017
41 citations
41 citations
2249 days before retraction
Regulation of Cancer Cell Behavior by the Small GTPase Rab13
Maria S. Ioannou, Peter S. McPherson
Journal of Biological Chemistry
Open Access
Published: Apr 2016
47 citations
47 citations
2520 days before retraction
Prediction of drugs having opposite effects on disease genes in a directed network
Hasun Yu, Sungji Choo, Junseok Park et al. (6 authors)
BMC Systems Biology
Open Access
Published: Jan 2016
31 citations
31 citations
2605 days before retraction
Resistance to Kinase Inhibitors in Poorly Differentiated and Anaplastic Thyroid Cancer: Preclinical In vitro Evidences
F GianAA, D. Tumino, Francesco Frasca
Endocrinology & Metabolic Syndrome
Published: Jan 2016
1 citation
1 citation
2615 days before retraction
Novel binding partners of PBF in thyroid tumourigenesis
Neil Sharma
Unknown Journal
Published: Dec 2014
3011 days before retraction
Quick Stats
Total Citations:
19
Years Since Retraction:
2.7 years
Open Access:
Yes
Last Checked:
Jul 24, 2025